Brought to you by:
How the RevCore and VenaCore thrombectomy catheters combine to broaden treatment approach among advanced deep vein thrombosis patients previously limited to few options
This advertorial is sponsored by Inari Medical. For Joseph M. Liechty, MD, a vascular surgeon with Texas Vascular Associates in Plano, Texas, the emergence of the RevCoreTM and VenaCoreTM devices (Inari Medical) have helped broaden his treatment strategies for advanced…
VenaCore device offers long-awaited interventional solution for challenging venous occlusions
This advertorial is sponsored by Inari Medical. Despite the recent growth in mechanical thrombectomy devices for acute deep vein thrombosis (DVT), interventional options for wall adherent venous obstruction are extremely limited. Residual venous obstruction after medical or interventional therapy for…
Six-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit in acute DVT patients demonstrate ‘promise’
The open-label phase of the DEXTERITY-AFP trial investigating the Bullfrog microinfusion device—which involves the perivenous injection of the anti-inflammatory drug dexamethasone to improve patency and post-thrombotic syndrome (PTS) six months after thrombus removal in symptomatic deep vein thrombosis (DVT) patients—has…
One-year CLOUT data demonstrate low rate of PTS following treatment with ClotTriever
David Dexter (Sentara Vascular Specialists, Norfolk, USA) shared one-year data from the CLOUT registry this week at The VEINS 2023 (28–30 October, Las Vegas, USA). Long-term, prospective outcome data after mechanical thrombectomy for deep vein thrombosis (DVT) are lacking. The…
Primary patency after venous stenting best in NIVL patients, study finds
A recent study concludes that non-thrombotic iliac vein lesion (NIVL) patients have better primary patency after venous stenting than patients with venous thrombotic disorders. Olivier Espitia (CHU de Nantes, Nantes, France) and colleagues report this main finding from a multicenter…
Meta-analysis of PTS finds one in five at risk of long-term symptoms following isolated distal DVT
A meta-analysis is first to report the pooled risk of post-thrombotic syndrome (PTS) after isolated distal deep vein thrombosis (DVT). Researchers revealed a one-in-five risk of long-term PTS after isolated distal DVT, with one in 50 patients progressing to severe…
Abre stent data show ‘struggle to maintain patency’ among post-thrombotic syndrome patients
The Abre venous stent demonstrated three-year primary patency rates of 97.1%, 76.5% and 70.4% respectively for non-thrombotic iliac vein lesion (NIVL), acute deep vein thrombosis (DVT), and post-thrombotic syndrome (PTS) patient populations within the ABRE clinical study, a late-breaking session…
CLTI, VTE and post-thrombotic syndrome: Leading experts discuss crucial decision-making in interventional approaches
This advertorial is sponsored by ACHL. For Anahita Dua, MBChB, the stark realities and complexities of peripheral arterial disease (PAD) patients undergoing endovascular treatment for chronic limb-threatening ischemia (CLTI) coalesce into one important truth: the necessity of entering the operating…